New drug shows promise for Near-Total skin clearance in psoriasis

NCT ID NCT03410992

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

Summary

This study tested an investigational drug called bimekizumab in adults with moderate to severe plaque psoriasis. It was a large, late-stage trial comparing the drug to a placebo to see how well it cleared skin and reduced symptoms like itch and pain. The main goal was to see if patients achieved 90% skin improvement after 16 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ps0013 003

Carlton, Australia
Ps0013 006

Kogarah, Australia
Ps0013 008

East Melbourne, Australia
Ps0013 200

Schwerin, Germany
Ps0013 202

Hamburg, Germany
Ps0013 204

Witten, Germany
Ps0013 219

Münster, Germany
Ps0013 220

Hamburg, Germany
Ps0013 250

Szolnok, Hungary
Ps0013 253

Orosháza, Hungary
Ps0013 258

Veszprém, Hungary
Ps0013 260

Szeged, Hungary
Ps0013 261

Budapest, Hungary
Ps0013 262

Miskolc, Hungary
Ps0013 350

Warsaw, Poland
Ps0013 351

Warsaw, Poland
Ps0013 352

Gdansk, Poland
Ps0013 353

Szczecin, Poland
Ps0013 354

Warsaw, Poland
Ps0013 355

Bialystok, Poland
Ps0013 356

Lublin, Poland
Ps0013 357

Kielce, Poland
Ps0013 358

Katowice, Poland
Ps0013 359

Katowice, Poland
Ps0013 360

Lodz, Poland
Ps0013 361

Bialystok, Poland
Ps0013 363

Krakow, Poland
Ps0013 365

Wroclaw, Poland
Ps0013 366

Katowice, Poland
Ps0013 368

Wroclaw, Poland
Ps0013 369

Bialystok, Poland
Ps0013 370

Wroclaw, Poland
Ps0013 374

Poznan, Poland
Ps0013 400

Moscow, Russia
Ps0013 401

Saratov, Russia
Ps0013 402

Moscow, Russia
Ps0013 403

Moscow, Russia
Ps0013 404

Saint Petersburg, Russia
Ps0013 405

Saint Petersburg, Russia
Ps0013 406

Yaroslavl, Russia
Ps0013 550

Manchester, United Kingdom
Ps0013 554

Reading, United Kingdom
Ps0013 555

Salford, United Kingdom
Ps0013 657

Waterloo, Canada
Ps0013 658

Ajax, Canada
Ps0013 660

Montreal, Canada
Ps0013 663

Mississauga, Canada
Ps0013 665

Québec, Canada
Ps0013 667

Ottawa, Canada
Ps0013 668

North Bay, Canada
Ps0013 671

Hamilton, Canada
Ps0013 672

Edmonton, Canada
Ps0013 675

Markham, Canada
Ps0013 676

Surrey, Canada
Ps0013 701

Busan, South Korea
Ps0013 703

Seoul, South Korea
Ps0013 705

Seongnam-si, South Korea
Ps0013 901

Portsmouth, New Hampshire, 03801, United States
Ps0013 914

San Antonio, Texas, 78213, United States
Ps0013 919

San Diego, California, 92103, United States
Ps0013 928

Fort Myers, Florida, 33912, United States
Ps0013 929

Portland, Oregon, 97223, United States
Ps0013 933

Murray, Utah, 84107, United States
Ps0013 937

Johnston, Rhode Island, 02919, United States
Ps0013 940

Beverly, Massachusetts, 01915, United States
Ps0013 944

New Orleans, Louisiana, 70115, United States
Ps0013 947

Buffalo, New York, 14221, United States
Ps0013 949

Cleveland, Ohio, 44106-1716, United States
Ps0013 954

Skokie, Illinois, 60077, United States
Ps0013 955

San Diego, California, 92123, United States
Ps0013 956

Verona, New Jersey, 07044-2946, United States
Ps0013 962

Owensboro, Kentucky, 42303, United States
Ps0013 963

Rochester, New York, 14623, United States
Ps0013 965

New York, New York, 10025, United States
Ps0013 966

Sandy Springs, Georgia, 30329, United States
Ps0013 967

Santa Monica, California, 90404, United States
Ps0013 968

New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC PLAQUE PSORIASIS MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PSORIATIC ARTHRITIS